TY - JOUR
T1 - Impact of anca-associated vasculitis on outcomes of hospitalizations for goodpasture’s syndrome in the united states
T2 - Nationwide inpatient sample 2003–2014
AU - Thongprayoon, Charat
AU - Kaewput, Wisit
AU - Boonpheng, Boonphiphop
AU - Ungprasert, Patompong
AU - Bathini, Tarun
AU - Srivali, Narat
AU - Vallabhajosyula, Saraschandra
AU - Castaneda, Jorge L.
AU - Monga, Divya
AU - Kanduri, Swetha R.
AU - Medaura, Juan
AU - Cheungpasitporn, Wisit
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/3
Y1 - 2020/3
N2 - Background and objectives: Goodpasture’s syndrome (GS) is a rare, life-threatening autoimmune disease. Although the coexistence of anti-neutrophil cytoplasmic antibody (ANCA) with Goodpasture’s syndrome has been recognized, the impacts of ANCA vasculitis on mortality and resource utilization among patients with GS are unclear. Materials and Methods: We used the National Inpatient Sample to identify hospitalized patients with a principal diagnosis of GS from 2003 to 2014 in the database. The predictor of interest was the presence of ANCA-associated vasculitis. We tested the differences concerning in-hospital treatment and outcomes between GS patients with and without ANCA-associated vasculitis using logistic regression analysis with adjustment for other clinical characteristics. Results: A total of 964 patients were primarily admitted to hospital for GS. Of these, 84 (8.7%) had a concurrent diagnosis of ANCA-associated vasculitis. Hemoptysis was more prevalent in GS patients with ANCA-associated vasculitis. During hospitalization, GS patients with ANCA-associated required non-significantly more mechanical ventilation and non-invasive ventilation support, but non-significantly less renal replacement therapy and plasmapheresis than those with GS alone. There was no significant difference in in-hospital outcomes, including organ failure and mortality, between GS patients with and without ANCA-associated vasculitis. Conclusions: Our study demonstrated no significant differences between resource utilization and in-hospital mortality among hospitalized patients with coexistence of ANCA vasculitis and GS, compared to those with GS alone.
AB - Background and objectives: Goodpasture’s syndrome (GS) is a rare, life-threatening autoimmune disease. Although the coexistence of anti-neutrophil cytoplasmic antibody (ANCA) with Goodpasture’s syndrome has been recognized, the impacts of ANCA vasculitis on mortality and resource utilization among patients with GS are unclear. Materials and Methods: We used the National Inpatient Sample to identify hospitalized patients with a principal diagnosis of GS from 2003 to 2014 in the database. The predictor of interest was the presence of ANCA-associated vasculitis. We tested the differences concerning in-hospital treatment and outcomes between GS patients with and without ANCA-associated vasculitis using logistic regression analysis with adjustment for other clinical characteristics. Results: A total of 964 patients were primarily admitted to hospital for GS. Of these, 84 (8.7%) had a concurrent diagnosis of ANCA-associated vasculitis. Hemoptysis was more prevalent in GS patients with ANCA-associated vasculitis. During hospitalization, GS patients with ANCA-associated required non-significantly more mechanical ventilation and non-invasive ventilation support, but non-significantly less renal replacement therapy and plasmapheresis than those with GS alone. There was no significant difference in in-hospital outcomes, including organ failure and mortality, between GS patients with and without ANCA-associated vasculitis. Conclusions: Our study demonstrated no significant differences between resource utilization and in-hospital mortality among hospitalized patients with coexistence of ANCA vasculitis and GS, compared to those with GS alone.
KW - ANCA
KW - Anti-GBM disease
KW - Goodpasture syndrome
KW - Hospitalization
KW - Outcomes
KW - Vasculitis
UR - http://www.scopus.com/inward/record.url?scp=85080973535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080973535&partnerID=8YFLogxK
U2 - 10.3390/medicina56030103
DO - 10.3390/medicina56030103
M3 - Article
C2 - 32121573
AN - SCOPUS:85080973535
SN - 1010-660X
VL - 56
JO - Medicina (Lithuania)
JF - Medicina (Lithuania)
IS - 3
M1 - 103
ER -